TheraRadar
Data updated: May 26, 2026

AVYCAZ (avibactam sodium)

Infectious Disease Approved 2015-02-25

AVYCAZ is indicated for the treatment of Complicated Intra-abdominal Infections; Complicated Urinary Tract Infections; Pyelonephritis; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia.

Source: FDA Label • AbbVie

How AVYCAZ Works

AVYCAZ consists of two active components: ceftazidime and avibactam. Ceftazidime is a bactericidal cephalosporin that inhibits bacterial cell wall synthesis by binding to essential penicillin-binding proteins (PBPs). Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by certain beta-lactamases, including Ambler Class A (e.g., KPC), Class C (e.g., AmpC), and some Class D (e.g., OXA-48) enzymes. This combination restores ceftazidime's activity against many resistant Gram-negative pathogens.

7
Indications
--
Phase 3 Trials
7
Priority Reviews
11
Years on Market

Details

Status
Prescription
First Approved
2015-02-25
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVENOUS
Dosage Forms
POWDER

Companies

Active Ingredient: AVIBACTAM SODIUM , CEFTAZIDIME

AVYCAZ Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
12 FDA actions from 2015 to 2025 · 6 indication expansions
Apr 2025 SUPPL
Label · Labeling
Feb 2025 SUPPL
Label · Labeling
Jan 2024 SUPPL Priority
Efficacy

What AVYCAZ Treats

5 indications

AVYCAZ is approved for 5 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Complicated Intra-abdominal Infections
  • Complicated Urinary Tract Infections
  • Pyelonephritis
  • Hospital-acquired Bacterial Pneumonia
  • Ventilator-associated Bacterial Pneumonia
Source: FDA Label

AVYCAZ Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AVYCAZ

3 of 17

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ZERBAXA
CEFTOLOZANE SULFATE
5 shared
CUBIST PHARMS LLC
Shared indications:
Complicated Intra-abdominal InfectionsComplicated Urinary Tract InfectionsPyelonephritis +2 more
RECARBRIO
CILASTATIN SODIUM
3 shared
Merck
Shared indications:
Hospital-Acquired Bacterial PneumoniaVentilator-Associated Bacterial PneumoniaPyelonephritis
AVELOX
MOXIFLOXACIN HYDROCHLORIDE
1 shared
Bayer
Shared indications:
Complicated Intra-Abdominal Infections
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AVYCAZ FDA Label Details

Indications & Usage

FDA Label (PDF)

AVYCAZ is indicated for the treatment of Complicated Intra-abdominal Infections; Complicated Urinary Tract Infections; Pyelonephritis; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia.

View full patent landscape →
7 OB patents · 4 families · 273 international docs across 58 countries

AVYCAZ Patents & Exclusivity

Latest Patent: Jun 2032
Exclusivity: Jan 2027

Patents (7 active)

US9284314 Expires Jun 15, 2032
US8969566 Expires Jun 15, 2032
US9695122 Expires Jun 15, 2032
US8471025 Expires Aug 12, 2031
US8835455 Expires Oct 8, 2030
US7612087 Expires Nov 12, 2026
US7112592 Expires Jan 7, 2026

Exclusivity

NPP Until Jan 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for AVYCAZ

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 10 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 17 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.